- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00934492
Cotrimoxazole Prophylaxis in Severely Malnourished Children (CTX)
Randomized, Placebo Controlled Trial of Cotrimoxazole Prophylaxis Amongst HIV-uninfected Children With Severe Malnutrition
This trial aims to test the hypothesis that mortality among Kenyan children with severe malnutrition following initial stabilisation is due to ongoing vulnerability to infectious disease, and that long term daily co-trimoxazole prophylaxis will reduce mortality.
The objective is to conduct a randomized, double blind, placebo-controlled trial of cotrimoxazole prophylaxis for 6 months among HIV-uninfected children with severe malnutrition following stabilization. The primary outcome will be survival at one year. Secondary outcomes are toxicity, growth, the frequency and causes of hospitalisation and microbial resistance to antibiotics.
Cotrimoxazole has striking protective efficacy against mortality among children with HIV, despite not altering the underlying immune deficiency. It is hypothesised that co-trimoxazole prophylaxis will have a similar effect in children immunocompromised because of severe malnutrition. Worldwide, severe malnutrition is commoner than HIV in childhood and co-trimoxazole is cheap and widely available, making it easily translatable to policy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Malnutrition is the most important underlying risk factor for childhood death in developing countries. Severely malnourished children are at greatly increased risk of death from infectious diseases in the community, in hospital and following discharge. Malnutrition and infection are synergistic, in part because malnutrition causes secondary immune deficiency, whilst infections cause losses and diversion of nutrients. This synergy is exacerbated by a high level of exposure to pathogens. Among children treated for severe malnutrition in Africa, mortality following discharge from hospitals ranges between 8% and 41%.
Cotrimoxazole is a synthetic antibacterial combination that blocks two steps of folate metabolism involved in the biosynthesis of nucleic acids and proteins essential to many bacteria and some parasites, including Plasmodium falciparum. It is cheap, widely available and has an established safety profile in African populations. Cotrimoxazole prophylaxis dramatically reduces mortality among children with HIV, irrespective of the degree of immune suppression. The primary effect is in reducing bacterial infection, especially pneumonia. the effect has been demonstrated in areas with high levels of cotrimoxazole resistance bacteria. It is also widely used in developed countries among children with other immune deficiencies to prevent infection. Children with severe malnutrition are immune deficient, as evidenced by their susceptibility to infectious diseases, and may therefore benefit from daily antimicrobial prophylaxis.
The objective is to conduct a randomized, double blind, placebo-controlled trial of cotrimoxazole prophylaxis for 6 months among HIV-uninfected children with severe malnutrition following stabilization. The primary outcome will be survival at one year. Secondary outcomes are toxicity, growth, hospitalisation, microbial resistance in carriage and pathogenic organisms and markers of inflammation and immune function.
On 26th September 2012, on advice from an independent senior statistician who reviewed the actual event rate in the control arm, the rates of recruitment and loss to follow up, the Trial Steering Committee recommended that the trial team to recruit at least 1750 participants to achieve the original objective of having >90% power to detect a reduction in mortality during 12 months follow up of 33%. Recruitment was stopped on 31st March 2013 at 1781 participants.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Nairobi, Kenya
- Mbagathi District Hospital
-
-
Coast
-
Kilifi, Coast, Kenya, 80108
- KEMRI/Wellcome Trust Research Programme
-
Malindi, Coast, Kenya
- Malindi District Hospital
-
Mombasa, Coast, Kenya
- Coast Provincial General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 2 months to 5 years
- Admitted to hospital
- Severe malnutrition: age 6 months to 5 years: MUAC <11cm; age 2 to 6 months: MUAC for age <-3 z scores compared to the WHO growth standards; or kwashiorkor at any age (defined in current WHO guidelines) for enrollments up to 24th March 2011.
- Severe malnutrition:age 6 months to 5 years: MUAC <11.5cm; age 2 to 6 months: MUAC <11.0cm; or kwashiorkor at any age (defined in current WHO guidelines) for enrollments from 24th March 2011, following protocol amendment.
- HIV rapid test negative, or if under 18 months, PCR negative and no longer breastfeeding for at least 6 weeks
- Planning to remain within study area and willing to come for all protocol specified visits
Exclusion Criteria:
- Refusal to give informed consent
- Cotrimoxazole is specifically contra-indicated (e.g. porphyria)
- Known hypersensitivity reaction to sulpha drugs or trimethoprim
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Cotrimoxazole dispersible tablet
Children between 2-6 months will receive single dispersible tablet of 120mg,daily while children over 6 months to 5 years will receive 240 mg dispersible tablet daily for six months.
|
Cotrimoxazole dispersible tablets 120/240mg daily for six consecutive months.
Other Names:
|
PLACEBO_COMPARATOR: Placebo dispersible tablet
Children between 2-6 months will receive single dispersible Placebo tablet of 120mg,daily while children over 6 months to 5 years will receive 240 mg dispersible Placebo tablet daily for six months.
|
Placebo dispersible tablets 120/240mg daily for six consecutive months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mortality
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency and causes of hospital re-admission
Time Frame: 12 months
|
12 months
|
Growth
Time Frame: 12 months
|
12 months
|
Microbial population and antimicrobial resistance
Time Frame: 12 months
|
12 months
|
Immune activation and inflammatory markers; markers of immune function
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: James A Berkley, FRCPCH, Universitiy of Oxford & Kenya Medical Research Institute
Publications and helpful links
General Publications
- Ngari MM, Iversen PO, Thitiri J, Mwalekwa L, Timbwa M, Fegan GW, Berkley JA. Linear growth following complicated severe malnutrition: 1-year follow-up cohort of Kenyan children. Arch Dis Child. 2019 Mar;104(3):229-235. doi: 10.1136/archdischild-2018-315641. Epub 2018 Sep 28.
- Ngari MM, Mwalekwa L, Timbwa M, Hamid F, Ali R, Iversen PO, Fegan GW, Berkley JA. Changes in susceptibility to life-threatening infections after treatment for complicated severe malnutrition in Kenya. Am J Clin Nutr. 2018 Apr 1;107(4):626-634. doi: 10.1093/ajcn/nqy007.
- Ngari MM, Thitiri J, Mwalekwa L, Timbwa M, Iversen PO, Fegan GW, Berkley JA. The impact of rickets on growth and morbidity during recovery among children with complicated severe acute malnutrition in Kenya: A cohort study. Matern Child Nutr. 2018 Apr;14(2):e12569. doi: 10.1111/mcn.12569. Epub 2017 Nov 27.
- Berkley JA, Ngari M, Thitiri J, Mwalekwa L, Timbwa M, Hamid F, Ali R, Shangala J, Mturi N, Jones KD, Alphan H, Mutai B, Bandika V, Hemed T, Awuondo K, Morpeth S, Kariuki S, Fegan G. Daily co-trimoxazole prophylaxis to prevent mortality in children with complicated severe acute malnutrition: a multicentre, double-blind, randomised placebo-controlled trial. Lancet Glob Health. 2016 Jul;4(7):e464-73. doi: 10.1016/S2214-109X(16)30096-1. Epub 2016 Jun 2.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SSC 1562
- OXTREC 18 09
- WT 083579
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nutrition Disorders
-
NestléCompletedNutrition Disorder, ChildUnited Kingdom
-
Universidad de MonterreyFEMSA Foundation; Mexican Food BanksCompletedMalnutrition | Malnutrition, Child | Malnutrition in Children | Child Malnutrition | Child Overnutrition | Nutrition Disorders, ChildMexico
-
Harran UniversityRecruitingNutrition | Nutrition Disorder, InfantTurkey
-
Jimma UniversityUnknown
-
Danone Early Life Nutrition BrazilUniversidade Federal do Rio Grande do Norte; Federal University of Health Science... and other collaboratorsCompletedChild Nutrition Disorders
-
Lata Medical Research Foundation, NagpurNational Health and Medical Research Council, Australia; Dimagi Inc.; ADVANCING...Unknown
-
Augusta UniversityActive, not recruiting
-
FHI 360United States Agency for International Development (USAID); UNICEF; Ministry...TerminatedBreast Feeding | Nutrition | Child MalnutritionAfghanistan
-
Nemours Children's ClinicChildren's Hospital Medical Center, CincinnatiNot yet recruitingBody Composition | Feeding; Difficult, Newborn | Nutrition Disorder, InfantUnited States
-
NestléWithdrawnEnteral Feeding Intolerance | Tube Feeding | Nutrition Disorder, ChildUnited States
Clinical Trials on Cotrimoxazole dispersible tablet
-
University Hospital, Basel, SwitzerlandCompleted
-
Chulalongkorn UniversityRecruitingPediatric HIV InfectionThailand
-
BayerCompletedPharmacokineticsGermany
-
Novartis PharmaceuticalsCompletedChronic Iron Overload Due to Transfusion-dependant AnemiasItaly, Austria, Thailand, Spain, Germany, Mexico, Malaysia, Greece, United Kingdom, France, Saudi Arabia, United Arab Emirates, Lebanon, Russian Federation, United States, Argentina
-
SpringWorks Therapeutics, Inc.Active, not recruitingPlexiform Neurofibroma | Neurofibromatosis Type 1 (NF1)United States
-
ALK-Abelló A/SITEC ServicesCompletedAllergic Rhinitis Due to House Dust Mite | Allergic Asthma Due to Dermatophagoides Farinae | Allergic Asthma Due to Dermatophagoides PteronyssinusFrance
-
International Centre for Diarrhoeal Disease Research...Completed
-
Suzana Erico Tanni MinamotoLiita Care ApSCompleted
-
sigma-tau i.f.r. S.p.A.CompletedMalaria,FalciparumBurkina Faso, Congo, The Democratic Republic of the, Gambia, Mozambique, Tanzania
-
The First Affiliated Hospital with Nanjing Medical...Unknown